Search
forLearn
5 / 801 resultslearn KB solution
learn HT-B
learn vitamin k
learn vitamin b
Research
5 / 1000+ resultsresearch Anti‐keratin Monoclonal Antibody against Basal Cell Epithelioma Keratin: BKN‐1
BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.
research ANTI‐HAIR KERATIN MONOCLONAL ANTIBODY (HKN‐2)
HKN-2 antibody targets specific skin and hair cells, showing keratin complexity.
research 1433 Role of BNC1 in keratinocytes proliferation and migration: A critical regulator of wound healing?
Basonuclin 1 (BNC1) helps skin cells multiply and move, which is crucial for wound healing.
research Characterization of Bsk mice: I. The Bsk mutation does not involve a recombination of cornea-specific keratin 12 and skin-specific hair keratin genes.
The Bsk mutation doesn't involve keratin gene recombination and its cause is unknown.
research LB1007 Systemic treatment with a KLK5 inhibitor shows efficacy in a murine model of Netherton syndrome
A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
Community Join
5 / 1000+ resultscommunity Breezula or kx-826 which one is better ?
Breezula (cb-03-01) and kx-826 are discussed as hair loss treatments. Kx-826 is available on Kintor's website, while Breezula is available on the grey market.
community Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
community RU58841 carrier - PG/Ethanol vs KB solution?
The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.
community How’s RCH-01 doing?
RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.